PHILADELPHIA – With lengthy development cycles and the increasing costs of clinical work, well-established therapeutics sitting on pharmaceutical company shelves may be the lowest hanging fruit.The question is: Who is going to pay for them? Big pharmas are challenged to bring all of the promising products to market, despite budget constraints; biotechs are challenged to find funding for their own technologies; and venture capital firms are challenged to get returns on investments.